DOP2012000281A - Composiciones farmaceuticas y metodos para su elaboracion - Google Patents
Composiciones farmaceuticas y metodos para su elaboracionInfo
- Publication number
- DOP2012000281A DOP2012000281A DO2012000281A DO2012000281A DOP2012000281A DO P2012000281 A DOP2012000281 A DO P2012000281A DO 2012000281 A DO2012000281 A DO 2012000281A DO 2012000281 A DO2012000281 A DO 2012000281A DO P2012000281 A DOP2012000281 A DO P2012000281A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- methods
- pharmaceutical compositions
- development
- pazopanib
- weight
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000003798 L01XE11 - Pazopanib Substances 0.000 abstract 2
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 abstract 2
- 229960000639 pazopanib Drugs 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33171510P | 2010-05-05 | 2010-05-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2012000281A true DOP2012000281A (es) | 2013-05-31 |
Family
ID=44851507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2012000281A DOP2012000281A (es) | 2010-05-05 | 2012-11-02 | Composiciones farmaceuticas y metodos para su elaboracion |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US20110281901A1 (enExample) |
| EP (1) | EP2566331B1 (enExample) |
| JP (1) | JP5835717B2 (enExample) |
| KR (1) | KR20130071434A (enExample) |
| CN (1) | CN102970871A (enExample) |
| AR (1) | AR081364A1 (enExample) |
| AU (1) | AU2011247995B2 (enExample) |
| BR (1) | BR112012028291A2 (enExample) |
| CA (1) | CA2798386A1 (enExample) |
| CL (1) | CL2012003075A1 (enExample) |
| CO (1) | CO6640262A2 (enExample) |
| CR (1) | CR20120556A (enExample) |
| DO (1) | DOP2012000281A (enExample) |
| EA (1) | EA201291168A1 (enExample) |
| ES (1) | ES2519615T3 (enExample) |
| IL (1) | IL222751A0 (enExample) |
| MA (1) | MA34286B1 (enExample) |
| MX (1) | MX2012012837A (enExample) |
| NZ (1) | NZ603411A (enExample) |
| PE (1) | PE20130217A1 (enExample) |
| PH (1) | PH12012502159A1 (enExample) |
| SG (1) | SG185087A1 (enExample) |
| TW (1) | TW201206908A (enExample) |
| UY (1) | UY33367A (enExample) |
| WO (1) | WO2011140343A1 (enExample) |
| ZA (1) | ZA201208265B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070020299A1 (en) | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| ES2493641T3 (es) * | 2007-06-28 | 2014-09-12 | Cydex Pharmaceuticals, Inc. | Administración nasal de soluciones acuosas de corticosteroides |
| US12370352B2 (en) | 2007-06-28 | 2025-07-29 | Cydex Pharmaceuticals, Inc. | Nasal and ophthalmic delivery of aqueous corticosteroid solutions |
| US8623395B2 (en) | 2010-01-29 | 2014-01-07 | Forsight Vision4, Inc. | Implantable therapeutic device |
| US10166142B2 (en) | 2010-01-29 | 2019-01-01 | Forsight Vision4, Inc. | Small molecule delivery with implantable therapeutic device |
| TW201206908A (en) * | 2010-05-05 | 2012-02-16 | Glaxo Wellcome Mfg Pte Ltd | Pharmaceutical compositions and methods of making same |
| HUE054113T2 (hu) | 2010-08-05 | 2021-08-30 | Forsight Vision4 Inc | Injekciós készülék gyógyszerbejuttatáshoz |
| EP2640360A2 (en) | 2010-11-19 | 2013-09-25 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
| SI2755600T1 (sl) | 2011-09-16 | 2021-08-31 | Forsight Vision4, Inc. | Naprava za izmenjavo tekočine |
| RU2014137190A (ru) * | 2012-02-17 | 2016-04-10 | Фармасайкликс, Инк. | Комбинации ингибитора гистон-деацетилазы и пазопаниба и их применение |
| EP3897032B1 (en) * | 2012-03-08 | 2025-04-30 | Samsung Electronics Co., Ltd. | Method for controlling services in wireless communication system |
| AU2014236455B2 (en) | 2013-03-14 | 2018-07-12 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
| ES2972168T3 (es) | 2013-03-28 | 2024-06-11 | Forsight Vision4 Inc | Implante oftálmico para administración de sustancias terapéuticas |
| US11136625B2 (en) | 2013-08-28 | 2021-10-05 | Crown Bioscience, Inc. (Taicang) | Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same |
| CA2957548A1 (en) * | 2014-08-08 | 2016-02-11 | Forsight Vision4, Inc. | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
| BR112017009660A2 (pt) | 2014-11-10 | 2017-12-19 | Forsight Vision4 Inc | dispositivos de administração de fármacos expansíveis e métodos de utilização |
| JP6818264B2 (ja) | 2014-12-25 | 2021-01-20 | 国立大学法人京都大学 | 高密度リポタンパク質およびその細胞親和性ペプチドを融合した高密度リポタンパク質の点眼による後眼部薬物デリバリー |
| AR108177A1 (es) | 2016-04-05 | 2018-07-25 | Forsight Vision4 Inc | Dispositivos de suministro de fármacos oculares implantables |
| EP3612223B1 (en) * | 2017-04-17 | 2024-07-31 | National Institute Of Biological Sciences, Beijing | Treating male senescence |
| TWI770246B (zh) * | 2017-08-02 | 2022-07-11 | 昊運股份有限公司 | 新穎化合物及包含其之醫藥組成物 |
| NZ805649A (en) * | 2018-06-07 | 2024-11-29 | Pfizer | Aqueous formulation comprising 1-(4-{ [4-(dimethylamino)piperidin-1-yl]carbonyl} phenyl)-3- [4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea |
| CN113350351A (zh) * | 2020-03-13 | 2021-09-07 | 青晓制药公司 | 帕唑帕尼的应用、药物组合物、注射液及制备方法和应用 |
| USD1033637S1 (en) | 2022-01-24 | 2024-07-02 | Forsight Vision4, Inc. | Fluid exchange device |
| US20240050429A1 (en) * | 2022-08-10 | 2024-02-15 | Qx Therapeutics, Inc. | Pazopanib pharmaceutical composition, injection and preparation method and use thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8904296D0 (sv) * | 1989-12-21 | 1989-12-21 | Pharmacia Ab | Transdermal system |
| US7893040B2 (en) * | 2005-07-22 | 2011-02-22 | Oculis Ehf | Cyclodextrin nanotechnology for ophthalmic drug delivery |
| US20080293691A1 (en) * | 2005-11-29 | 2008-11-27 | Smithkline Beecham Corporation | Treatment Method |
| AR059066A1 (es) * | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
| CA2650922C (en) * | 2006-04-18 | 2015-09-29 | Ekr Therapeutics, Inc. | Pre-mixed, ready-to-use pharmaceutical compositions |
| ES2830024T3 (es) * | 2007-10-19 | 2021-06-02 | Novartis Ag | Composiciones y métodos para el tratamiento del edema macular |
| JP5608099B2 (ja) * | 2008-01-30 | 2014-10-15 | ジェネンテック， インコーポレイテッド | ピラゾロピリミジンｐｉ３ｋ阻害剤化合物および使用方法 |
| JP2012533562A (ja) * | 2009-07-16 | 2012-12-27 | グラクソ ウェルカム マニュファクチュアリング ピーティーイー リミテッド | 治療法 |
| US20120232102A1 (en) * | 2009-09-30 | 2012-09-13 | Chun-Fang Xu | Methods Of Administration And Treatment |
| UY33164A (es) * | 2010-01-06 | 2011-08-31 | Glaxo Wellcome Mfg Pte Ltd | Metodo de tratamiento |
| TW201206908A (en) * | 2010-05-05 | 2012-02-16 | Glaxo Wellcome Mfg Pte Ltd | Pharmaceutical compositions and methods of making same |
| US20130023550A1 (en) * | 2010-05-05 | 2013-01-24 | Glaxo Wellcome Manufacturing Pte, Ltd | Pharmaceutical compositions and methods of making same |
-
2011
- 2011-05-03 TW TW100115488A patent/TW201206908A/zh unknown
- 2011-05-03 UY UY0001033367A patent/UY33367A/es unknown
- 2011-05-03 AR ARP110101514A patent/AR081364A1/es unknown
- 2011-05-05 MA MA35417A patent/MA34286B1/fr unknown
- 2011-05-05 US US13/101,689 patent/US20110281901A1/en not_active Abandoned
- 2011-05-05 NZ NZ603411A patent/NZ603411A/en not_active IP Right Cessation
- 2011-05-05 PE PE2012002115A patent/PE20130217A1/es not_active Application Discontinuation
- 2011-05-05 KR KR1020127031739A patent/KR20130071434A/ko not_active Withdrawn
- 2011-05-05 US US13/133,030 patent/US20120028918A1/en not_active Abandoned
- 2011-05-05 MX MX2012012837A patent/MX2012012837A/es active IP Right Grant
- 2011-05-05 WO PCT/US2011/035363 patent/WO2011140343A1/en not_active Ceased
- 2011-05-05 EP EP11778348.0A patent/EP2566331B1/en active Active
- 2011-05-05 EA EA201291168A patent/EA201291168A1/ru unknown
- 2011-05-05 CN CN2011800333447A patent/CN102970871A/zh active Pending
- 2011-05-05 ES ES11778348.0T patent/ES2519615T3/es active Active
- 2011-05-05 JP JP2013509268A patent/JP5835717B2/ja not_active Expired - Fee Related
- 2011-05-05 PH PH1/2012/502159A patent/PH12012502159A1/en unknown
- 2011-05-05 AU AU2011247995A patent/AU2011247995B2/en not_active Ceased
- 2011-05-05 SG SG2012079968A patent/SG185087A1/en unknown
- 2011-05-05 CA CA2798386A patent/CA2798386A1/en not_active Abandoned
- 2011-05-05 BR BR112012028291A patent/BR112012028291A2/pt not_active IP Right Cessation
-
2012
- 2012-10-29 IL IL222751A patent/IL222751A0/en unknown
- 2012-10-31 CL CL2012003075A patent/CL2012003075A1/es unknown
- 2012-11-01 CR CR20120556A patent/CR20120556A/es unknown
- 2012-11-02 ZA ZA2012/08265A patent/ZA201208265B/en unknown
- 2012-11-02 DO DO2012000281A patent/DOP2012000281A/es unknown
- 2012-12-05 CO CO12221016A patent/CO6640262A2/es not_active Application Discontinuation
-
2015
- 2015-05-06 US US14/705,298 patent/US20150231265A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TW201206908A (en) | 2012-02-16 |
| CL2012003075A1 (es) | 2013-03-08 |
| AR081364A1 (es) | 2012-08-29 |
| US20120028918A1 (en) | 2012-02-02 |
| US20150231265A1 (en) | 2015-08-20 |
| AU2011247995A1 (en) | 2012-12-13 |
| MX2012012837A (es) | 2013-01-24 |
| EP2566331A1 (en) | 2013-03-13 |
| BR112012028291A2 (pt) | 2015-09-15 |
| EP2566331A4 (en) | 2013-09-18 |
| HK1175947A1 (en) | 2013-07-19 |
| IL222751A0 (en) | 2012-12-31 |
| US20110281901A1 (en) | 2011-11-17 |
| JP2013525501A (ja) | 2013-06-20 |
| CA2798386A1 (en) | 2011-11-10 |
| SG185087A1 (en) | 2012-12-28 |
| NZ603411A (en) | 2014-10-31 |
| EP2566331B1 (en) | 2014-09-03 |
| EA201291168A1 (ru) | 2013-06-28 |
| UY33367A (es) | 2011-10-31 |
| KR20130071434A (ko) | 2013-06-28 |
| CO6640262A2 (es) | 2013-03-22 |
| WO2011140343A1 (en) | 2011-11-10 |
| JP5835717B2 (ja) | 2015-12-24 |
| ZA201208265B (en) | 2013-07-31 |
| PH12012502159A1 (en) | 2013-02-04 |
| AU2011247995B2 (en) | 2014-07-31 |
| MA34286B1 (fr) | 2013-06-01 |
| CR20120556A (es) | 2013-02-20 |
| CN102970871A (zh) | 2013-03-13 |
| PE20130217A1 (es) | 2013-03-21 |
| ES2519615T3 (es) | 2014-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2012000281A (es) | Composiciones farmaceuticas y metodos para su elaboracion | |
| CY1122853T1 (el) | Σταθερα σκευασματα λινακλοτιδης | |
| BR112015004984A2 (pt) | formulações aquosas estáveis de adalimumab | |
| TR201905586T4 (tr) | Amorf dapagli̇flozi̇n i̇çeren formülasyonlar | |
| MX2019001253A (es) | Conjugados de proteina-agente activo y metodo para su preparacion. | |
| MX2022003458A (es) | Una composicion farmaceutica que comprende nanoparticulas hibridas amorfas estables, de al menos un inhibidor de proteina quinasa y al menos un componente estabilizador polimerico y formador de matriz. | |
| CU20130082A7 (es) | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr | |
| MX2014000201A (es) | Composiciones y metodos para mejorar el estado bioenergetico en celulas germinales femeninas. | |
| DOP2011000382A (es) | Sulfonamidas heterociclicas, usos y composiciones farmaceuticas de las mismas | |
| CY1123456T1 (el) | Μεθοδος παρασκευης οπτικως καθαρων και προαιρετικως υποκατεστημενων παραγωγων 2-(1-υδροξυ-αλκυλ)-χρωμεν-4-ονης και χρηση αυτων στην παρασκευη φαρμακευτικων ουσιων | |
| BR112012033755A2 (pt) | composições e métodos antissépticos estáveis | |
| HN2010002518A (es) | Composicion farmaceutica que comprende una sal de estroncio, vitamina d y una ciclodextrina | |
| CR20120542A (es) | HETEROARIL-CICLOHEXIL-TETRAAZABENZO [e] AZULENOS | |
| MX375715B (es) | Profarmacos de metilfenidato, procesos de elaboración y uso de los mismos. | |
| BR112013000254A2 (pt) | derivados heterocíclicos 1-fenil-substituídos e seu uso como moduladores do receptor de prostaglandina d2 | |
| ECSP13012667A (es) | Compuestos de triazolopiridina | |
| MX340983B (es) | Composiciones farmaceuticas y nutraceuticas de acido abscisico. | |
| BR112015009229A2 (pt) | composição tendo como alvo a expressão de genes para plaquetas, célula tronco hematopoiética, uso da referida célula tronco e método in vitro ou ex vivo para gerar uma célula tronco modificada | |
| BR112014027582A8 (pt) | composições oftalmicas com proteção e retenção de dessecação aperfeiçoada | |
| BR112014012459A2 (pt) | 2h-indazóis como antagonistas do receptor de ep2 | |
| CR20130318A (es) | Nuevos compuestos de benzodioxol-piperazina | |
| CY1125270T1 (el) | Βελτιωσεις σε και σχετιζομενες με συνθεσεις | |
| BR112015007823A2 (pt) | derivados de ácido hialurônico modificado e uso dos mesmos | |
| CO6460763A2 (es) | Métodos y formulaciones ectoparasiticidas | |
| BR112014010166A2 (pt) | uso de uma composição para a fabricação de um produto para melhorar a pontuação na bateria de testes neuropsicológicos, método para avaliar a cognição de um indivíduo e uso de uma composição para a fabricação de um produto para tratar um indivíduo em necessidade da mesma |